Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

Table 2 Correlation between pretreatment PET parameters and tumor progression

Threshold	Parameters	Maximum		Mean		Median
Threshold	Parameters	r value	p value	r value	p value	r value	p value
2.5	SUVmax	-0.088	0.633	-0.128	0.486	-0.128	0.486
	TLG	-0.205	0.259	-0.073	0.691	-0.073	0.691
	MTV	-0.226	0.213	-0.066	0.721	-0.066	0.721
	HI	-0.209	0.250	-0.117	0.524	-0.117	0.524
	TLG	-0.232	0.201	0.073	0.691	0.073	0.691
40%	MTV	-0.250	0.168	0.066	0.721	0.066	0.721
	HI	-0.426	0.015	0.219	0.228	0.219	0.228
	TLG	-0.225	0.216	0.102	0.578	0.102	0.578
50%	MTV	-0.263	0.146	0.121	0.511	0.121	0.511
	HI	-0.612	< 0.001	0.190	0.298	0.190	0.298
	TLG	-0.195	0.286	0.051	0.781	0.051	0.781
60%	MTV	-0.253	0.162	0.073	0.691	0.073	0.691
	HI	-0.234	0.198	0.212	0.245	0.212	0.245
	TLG	-0.137	0.456	0.044	0.812	0.044	0.812
70%	MTV	-0.171	0.348	0.095	0.605	0.062	0.736
70%	HI	-0.205	0.261	-0.095	0.605	-0.095	0.605

ISSN: 1470-7330